A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas

Dora Dias-Santagata, Quynh Lam, Kristin Bergethon, Gabrielle M. Baker, A. John Iafrate, Dinesh Rakheja, Mai P. Hoang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Metastasizing adnexal carcinomas are rare; thus, currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional therapeutic approaches. We performed immunohistochemistry (epidermal growth factor receptor (EGFR), HER2, and CD117), EGFR and ERBB2 fluorescence in situ hybridization (FISH), and multiplexed SNaPshot genotyping (testing for recurrent mutations in 15 cancer genes including BRAF, EGFR, KRAS, PIK3CA, and TP53) on primary tumors and corresponding metastases of 14 metastasizing adnexal carcinomas (three apocrine, six eccrine, two hidradenocarcinomas, two porocarcinomas, and one aggressive digital papillary adenocarcinoma). Metastasis to regional lymph node was most common, followed by skin and then lungs. Follow-up was available in 12 patients (5 months to 8 years) with 1 died of widespread metastases. Although EGFR overexpression was a prevalent feature in this cohort, seen in 7/11 (64%) primary tumors and 10/14 (71%) metastases; FISH for EGFR gene amplification was negative in 9 tested primary tumors and 12 metastases. FISH of the one primary tumor and three metastases with 2 HER2 overexpression revealed a low level of ERBB2 gene amplification in one apocrine carcinoma and corresponding metastasis. CD117 expression was seen only in rare cases. PIK3CA (2/12, 17%) and TP53 (3/12, 25%) mutations were detected in two (one hidradenocarcinoma, one porocarcinoma) and three (one eccrine, one hidradenocarcinoma, and one aggressive digital papillary adenocarcinoma) cases, respectively. The role of EGFR inhibitor therapy in metastasizing adnexal carcinomas with protein overexpression remains unclear. Targeted therapy including PI3K pathway inhibitors might be a potential treatment for rare cases of adnexal carcinomas with metastases.

Original languageEnglish (US)
Pages (from-to)974-982
Number of pages9
JournalModern Pathology
Volume24
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Neoplasm Metastasis
Carcinoma
Epidermal Growth Factor Receptor
Fluorescence In Situ Hybridization
Papillary Adenocarcinoma
Gene Amplification
Therapeutics
Neoplasms
erbB-1 Genes
Mutation
Neoplasm Genes
Phosphatidylinositol 3-Kinases
Lymph Nodes
Immunohistochemistry
Guidelines
Lung
Skin
Pharmaceutical Preparations
Proteins

Keywords

  • adnexal neoplasm
  • EGFR
  • gene mutation
  • metastasis
  • PIK3CA
  • TP53

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Dias-Santagata, D., Lam, Q., Bergethon, K., Baker, G. M., Iafrate, A. J., Rakheja, D., & Hoang, M. P. (2011). A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Modern Pathology, 24(7), 974-982. https://doi.org/10.1038/modpathol.2011.48

A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. / Dias-Santagata, Dora; Lam, Quynh; Bergethon, Kristin; Baker, Gabrielle M.; Iafrate, A. John; Rakheja, Dinesh; Hoang, Mai P.

In: Modern Pathology, Vol. 24, No. 7, 07.2011, p. 974-982.

Research output: Contribution to journalArticle

Dias-Santagata, D, Lam, Q, Bergethon, K, Baker, GM, Iafrate, AJ, Rakheja, D & Hoang, MP 2011, 'A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas', Modern Pathology, vol. 24, no. 7, pp. 974-982. https://doi.org/10.1038/modpathol.2011.48
Dias-Santagata, Dora ; Lam, Quynh ; Bergethon, Kristin ; Baker, Gabrielle M. ; Iafrate, A. John ; Rakheja, Dinesh ; Hoang, Mai P. / A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. In: Modern Pathology. 2011 ; Vol. 24, No. 7. pp. 974-982.
@article{6dbc269ef7494aaf9b4ca41259cb8cb4,
title = "A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas",
abstract = "Metastasizing adnexal carcinomas are rare; thus, currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional therapeutic approaches. We performed immunohistochemistry (epidermal growth factor receptor (EGFR), HER2, and CD117), EGFR and ERBB2 fluorescence in situ hybridization (FISH), and multiplexed SNaPshot genotyping (testing for recurrent mutations in 15 cancer genes including BRAF, EGFR, KRAS, PIK3CA, and TP53) on primary tumors and corresponding metastases of 14 metastasizing adnexal carcinomas (three apocrine, six eccrine, two hidradenocarcinomas, two porocarcinomas, and one aggressive digital papillary adenocarcinoma). Metastasis to regional lymph node was most common, followed by skin and then lungs. Follow-up was available in 12 patients (5 months to 8 years) with 1 died of widespread metastases. Although EGFR overexpression was a prevalent feature in this cohort, seen in 7/11 (64{\%}) primary tumors and 10/14 (71{\%}) metastases; FISH for EGFR gene amplification was negative in 9 tested primary tumors and 12 metastases. FISH of the one primary tumor and three metastases with 2 HER2 overexpression revealed a low level of ERBB2 gene amplification in one apocrine carcinoma and corresponding metastasis. CD117 expression was seen only in rare cases. PIK3CA (2/12, 17{\%}) and TP53 (3/12, 25{\%}) mutations were detected in two (one hidradenocarcinoma, one porocarcinoma) and three (one eccrine, one hidradenocarcinoma, and one aggressive digital papillary adenocarcinoma) cases, respectively. The role of EGFR inhibitor therapy in metastasizing adnexal carcinomas with protein overexpression remains unclear. Targeted therapy including PI3K pathway inhibitors might be a potential treatment for rare cases of adnexal carcinomas with metastases.",
keywords = "adnexal neoplasm, EGFR, gene mutation, metastasis, PIK3CA, TP53",
author = "Dora Dias-Santagata and Quynh Lam and Kristin Bergethon and Baker, {Gabrielle M.} and Iafrate, {A. John} and Dinesh Rakheja and Hoang, {Mai P.}",
year = "2011",
month = "7",
doi = "10.1038/modpathol.2011.48",
language = "English (US)",
volume = "24",
pages = "974--982",
journal = "Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas

AU - Dias-Santagata, Dora

AU - Lam, Quynh

AU - Bergethon, Kristin

AU - Baker, Gabrielle M.

AU - Iafrate, A. John

AU - Rakheja, Dinesh

AU - Hoang, Mai P.

PY - 2011/7

Y1 - 2011/7

N2 - Metastasizing adnexal carcinomas are rare; thus, currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional therapeutic approaches. We performed immunohistochemistry (epidermal growth factor receptor (EGFR), HER2, and CD117), EGFR and ERBB2 fluorescence in situ hybridization (FISH), and multiplexed SNaPshot genotyping (testing for recurrent mutations in 15 cancer genes including BRAF, EGFR, KRAS, PIK3CA, and TP53) on primary tumors and corresponding metastases of 14 metastasizing adnexal carcinomas (three apocrine, six eccrine, two hidradenocarcinomas, two porocarcinomas, and one aggressive digital papillary adenocarcinoma). Metastasis to regional lymph node was most common, followed by skin and then lungs. Follow-up was available in 12 patients (5 months to 8 years) with 1 died of widespread metastases. Although EGFR overexpression was a prevalent feature in this cohort, seen in 7/11 (64%) primary tumors and 10/14 (71%) metastases; FISH for EGFR gene amplification was negative in 9 tested primary tumors and 12 metastases. FISH of the one primary tumor and three metastases with 2 HER2 overexpression revealed a low level of ERBB2 gene amplification in one apocrine carcinoma and corresponding metastasis. CD117 expression was seen only in rare cases. PIK3CA (2/12, 17%) and TP53 (3/12, 25%) mutations were detected in two (one hidradenocarcinoma, one porocarcinoma) and three (one eccrine, one hidradenocarcinoma, and one aggressive digital papillary adenocarcinoma) cases, respectively. The role of EGFR inhibitor therapy in metastasizing adnexal carcinomas with protein overexpression remains unclear. Targeted therapy including PI3K pathway inhibitors might be a potential treatment for rare cases of adnexal carcinomas with metastases.

AB - Metastasizing adnexal carcinomas are rare; thus, currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional therapeutic approaches. We performed immunohistochemistry (epidermal growth factor receptor (EGFR), HER2, and CD117), EGFR and ERBB2 fluorescence in situ hybridization (FISH), and multiplexed SNaPshot genotyping (testing for recurrent mutations in 15 cancer genes including BRAF, EGFR, KRAS, PIK3CA, and TP53) on primary tumors and corresponding metastases of 14 metastasizing adnexal carcinomas (three apocrine, six eccrine, two hidradenocarcinomas, two porocarcinomas, and one aggressive digital papillary adenocarcinoma). Metastasis to regional lymph node was most common, followed by skin and then lungs. Follow-up was available in 12 patients (5 months to 8 years) with 1 died of widespread metastases. Although EGFR overexpression was a prevalent feature in this cohort, seen in 7/11 (64%) primary tumors and 10/14 (71%) metastases; FISH for EGFR gene amplification was negative in 9 tested primary tumors and 12 metastases. FISH of the one primary tumor and three metastases with 2 HER2 overexpression revealed a low level of ERBB2 gene amplification in one apocrine carcinoma and corresponding metastasis. CD117 expression was seen only in rare cases. PIK3CA (2/12, 17%) and TP53 (3/12, 25%) mutations were detected in two (one hidradenocarcinoma, one porocarcinoma) and three (one eccrine, one hidradenocarcinoma, and one aggressive digital papillary adenocarcinoma) cases, respectively. The role of EGFR inhibitor therapy in metastasizing adnexal carcinomas with protein overexpression remains unclear. Targeted therapy including PI3K pathway inhibitors might be a potential treatment for rare cases of adnexal carcinomas with metastases.

KW - adnexal neoplasm

KW - EGFR

KW - gene mutation

KW - metastasis

KW - PIK3CA

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=79959921749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959921749&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.48

DO - 10.1038/modpathol.2011.48

M3 - Article

C2 - 21423156

AN - SCOPUS:79959921749

VL - 24

SP - 974

EP - 982

JO - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

JF - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

SN - 0893-3952

IS - 7

ER -